Switzerland-based bioscience research tool manufacturer Biognosys closed a CHF2.7m ($3m) series A round on Monday last week with participation from backers including Syngenta Ventures, the corporate venturing unit for agribusiness company Syngenta.
Ignacio Martinez, a principal in Syngenta Ventures, has joined Biognosys’ board.
Joining Syngenta Ventures in the round were ZKB Startup Finance, the corporate venturing division of the Cantonal Bank of Zurich, venture capital fund Redalpine Capital and angel investor Hellmut Kirchner. Redalpine previously invested an undisclosed amount in Biognosys’ 2009 seed round.
Founded in 2008 as a spin-off from technical university ETH Zurich, Biognosys specializes in the development of equipment to study proteins as part of diagnostic research for a range of diseases.
Oliver Rinner, chief executive officer of Biognosys, said: "The closing of this financing round reflects the investor’s confidence in Biognosys team and our proprietary targeted proteomics technology. Syngenta Ventures and the new investors are a great addition to our company. With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth."